Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Chief Financial Officer | January 12, 2026 | January 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date January 12, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 213,420 |
Reported balance
After 2026-01-14 transaction · row 1
1 source rowRow 1 · 2026-01-14 · Tax withholding · Disposed 2,293 · Balance 213,420 F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2: The shares were sold in multiple trades at prices ranging from $15.46 to $15.48. The price reported above reflects the weighted average sales price. F3: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.47 · Expires 2036-01-11 | Direct | 254,075 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 40,655 · Balance 254,075 F4: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 279,931 |
Reported balance
After 2026-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-12 · Grant · Acquired 25,856 · Balance 279,931 F5: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F6: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
F2: The shares were sold in multiple trades at prices ranging from $15.46 to $15.48. The price reported above reflects the weighted average sales price.
F3: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F4: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
F5: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F6: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2026 Filed Jan 14, 2026 23:02 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 2,293 | $15.47 | $35,472.71 |
DisclosureSEC source: 0001437749-26-001286 · rdgdoc.xml · nonDerivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,420 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $15.46 to $15.48. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:02 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 25,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001286 · rdgdoc.xml · derivative · entry 3 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,931 Underlying: Common Stock · 25,856 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:02 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,655 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001286 · rdgdoc.xml · derivative · entry 2 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,075 Underlying: Common Stock · 40,655 shares Expires 2036-01-11 F4 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 21:55 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Tax withholdingCommon Stock | 4,542 | $16.99 | $77,168.58 |
DisclosureSEC source: 0001437749-25-037743 · rdgdoc.xml · nonDerivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,713 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. F2 · price: The shares were sold in multiple trades at prices ranging from $16.94 to $17.07. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 21:55 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 5,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-037743 · rdgdoc.xml · derivative · entry 2 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,255 Underlying: Common Stock · 5,502 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F5 · derivative.exercise_date: The restricted stock units vest immediately as of the award date. F5 · derivative.expiration_date: The restricted stock units vest immediately as of the award date. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 21:14 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 2,631 | $16.02 | $42,148.62 |
DisclosureSEC source: 0001437749-25-027464 · rdgdoc.xml · nonDerivative · entry 2 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,753 F1 · price: The shares were sold in multiple trades at prices ranging from $16.01 to $16.43. The price reported above reflects the weighted average sales price. F2 · price: The shares were sold in multiple trades at prices ranging from $15.90 to $16.19. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:14 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 39,082 | $16.16 | $631,565.12 |
DisclosureSEC source: 0001437749-25-027464 · rdgdoc.xml · nonDerivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,299 F1 · price: The shares were sold in multiple trades at prices ranging from $16.01 to $16.43. The price reported above reflects the weighted average sales price. F2 · price: The shares were sold in multiple trades at prices ranging from $15.90 to $16.19. The price reported above reflects the weighted average sales price. F3 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 25,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000452 · rdgdoc.xml · derivative · entry 2 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,876 Underlying: Common Stock · 25,876 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 3, 2026, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,621 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000452 · rdgdoc.xml · derivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,621 Underlying: Common Stock · 38,621 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 3, 2029. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:21 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 144,677 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001437749-24-004369 · rdgdoc.xml · derivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,763 Underlying: Common Stock · 144,677 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 13, 2028. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:10 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (right to buy) · Derivative | 100,086 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001493152-23-006672 · ownership.xml · derivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,086 Underlying: Common Stock · 100,086 shares Expires 2033-02-19 F1 · date: Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023. F2 · derivative.exercise_date: The Shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027. Read SEC document |
| July 12, 2022 Filed Jul 18, 2022 20:32 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019653 · ownership.xml · derivative · entry 1 Gruber James R. · CIK 0001923165 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning July 12, 2023, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning July 12, 2023, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.